2015
DOI: 10.1016/j.phrp.2014.10.012
|View full text |Cite
|
Sign up to set email alerts
|

Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis

Abstract: ObjectivesDevelopment of an efficacious vaccine against brucellosis has been a challenge for scientists for many years. At present, there is no licensed vaccine against human brucellosis. To overcome this problem, currently, antigenic determinants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered as potential candidates to develop subunit vaccines.MethodsIn this study, Brucella abortus LPS was used for conjugation to Neisseria meningitidis serogroup B outer membrane vesicle (OMV) as carrier… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 19 publications
0
11
0
Order By: Relevance
“…Other bacteria were cultured in nutrient-agar. After 24 h incubation at 37 C, colonies were confirmed by a biochemical test, and stored at À70 C before use [21].…”
Section: Culture Of Bacteriamentioning
confidence: 99%
“…Other bacteria were cultured in nutrient-agar. After 24 h incubation at 37 C, colonies were confirmed by a biochemical test, and stored at À70 C before use [21].…”
Section: Culture Of Bacteriamentioning
confidence: 99%
“…This implies that the role of IL-10 in immune response is limited to offset the Th1 cytokines production rather an exaggerated proinflammatory response (Pasquali et al, 2001). Further, IL12, a cytokine which plays crucial role in activating interferon producing NK and T helper cells leads to antibacterial response mechanism (Zhan and Cheers, 1995;Siadat et al, 2015).…”
Section: Resultsmentioning
confidence: 99%
“…These properties make B. abortus LPS a safe adjuvant to be used in vaccine production with different antigens for eliciting immunostimulatory activities. For these reasons, several studies evaluated effectiveness of B. abortus LPS as a safe adjuvant in combination with different antigens for designing new vaccine formulation [35][36][37][38][39] or developing an efficacious subunit vaccine against brucellosis using B. abortus LPS conjugated to carrier protein [40,41].…”
Section: Discussionmentioning
confidence: 99%